Jump Financial, LLC Pds Biotechnology Corp Transaction History

Jump Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 21, 2024	SELL	$4.8 - $6.4 $361,440 - $481,920	-75,300 Reduced 81.49%	17,100 $86,000
Q3 2023 Nov 07, 2023	SELL	$4.8 - $6.4 $361,440 - $481,920	-75,300 Reduced 81.49%	17,100 $86,000
Q2 2023 Oct 21, 2024	BUY	$5.03 - $9.9 $120,362 - $236,897	23,929 Added 34.95%	92,400 $464,000
Q2 2023 Aug 07, 2023	BUY	$5.03 - $9.9 $120,362 - $236,897	23,929 Added 34.95%	92,400 $464,000
Q1 2023 Oct 21, 2024	BUY	$5.68 - $11.99 $388,915 - $820,967	68,471 New	68,471 $421,000
Q1 2023 May 03, 2023	BUY	$5.68 - $11.99 $251,856 - $531,648	44,341 Added 183.76%	68,471 $421,000
Q4 2022 Feb 13, 2023	BUY	$3.28 - $13.2 $79,146 - $318,516	24,130 New	24,130 $318,000
Q1 2022 May 12, 2022	SELL	$4.78 - $8.43 $166,831 - $294,223	-34,902 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$7.76 - $14.35 $65,789 - $121,659	8,478 Added 32.08%	34,902 $283,000
Q3 2021 Nov 12, 2021	BUY	$9.33 - $17.08 $246,535 - $451,321	26,424 New	26,424 $393,000

4.06M

253K

70.4K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $41.8M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.